The two drugs commonly in use- Sulfonylureas and Basal insulin are the alternative medication after Metformin, a widely accepted Type-2 diabetes treatment.
The study, published in the journal Journal of the American Medical Association (JAMA) Network Open, showed that patients who intake one of these two drugs are 36 per cent have more chance and twice to have cardiovascular harm. “People should know if the medications they are taking to treat their diabetes could lead to serious cardiovascular harm. This calls for a paradigm shift in the treatment of Type 2 diabetes,” said Matthew O’Brien, Assistant Professor from the Northwestern University in the US.
Physicians should consider prescribing newer grades of anti-diabetic medications, such as GLP-1 agonists (Liraglutide), SGLT-2 inhibitors (Empagliflozin)or DPP-4 inhibitors (Sitagliptin), more routinely after Metformin, rather than Sulfonylureas or Basal insulin, suggested the researchers. These drugs are normally expensive which is the main reason they are not commonly prescribed.
The study should urge the medical providers to consider about cardiovascular effects of these drugs in the course of diabetes treatment, and shift prescribing patterns to newer drugs that have even more benefits, the team said.